Wiltfang et al. [ |
1999 | 36/no control group | S100B serum level has advantage over ammonia serum level in detecting portal-systemic encephalopathy |
Vaquero et al. [ |
2003 | 54/no control group | S100B serum level has no correlation with HE severity and liver function |
Saleh et al. [ |
2007 | 43/9 | S100B level has correlation with HE (stages I and II), compared to healthy and cirrhotic patients without HE |
Isobe-Harima et al. [ |
2008 | 9/no control group | S100B serum level is higher in HE patients |
Duarte Rojo et al. [ |
2016 | 46/15 | S100B serum levels are higher in patients with cirrhosis and HE than in healthy subjects |
Toney et al. [ |
2019 | 82/no control group | no correlation between serum S100B level and severity of HE |
Strebel et al. [ |
2020 | 30/no control group | serum S100B protein level correlated with the presence of HE |
type A | acute liver failure | episodic | with triggering factors | minimal | covert |
type B | portosystemic bypass | persistent | I | ||
without triggering factors | II | overt | |||
type C | hepatic cirrhosis | recurrent | III | ||
IV |